Literature DB >> 886226

Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy.

T J Hahn, L R Halstead, J G Haddad.   

Abstract

Serum 25-hydroxyvitamin D (25OHD) concentrations were measured by competitive protein-binding assay in 21 patients who were receiving chronic prednisone therapy and who demonstrated radiologic osteopenia. Results were compared to values obtained in 19 matched non-steroid-treated control subjects. Serum 25OHD values in control and steroid-treated subjects were virtually identical and showed a similar positive correlation with vitamin D intake. To rule out possible assay interference by postulated steroid-induced abnormal vitamin D metabolites, 25OHD was specifically isolated from pooled extracts of control and steroid-treatment patient sera by silicic acid column chromatography. 25OHD levels were again identical in both groups, and there was no evidence of radioassayable abnormal metabolites. It is concluded that the maintenance of normal serum levels of 25OHD is not altered by chronic moderate dose corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 886226

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  15 in total

1.  Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus.

Authors:  Hyoun-Ah Kim; Jun-Mo Sung; Ja-Young Jeon; Jeong-Moon Yoon; Chang-Hee Suh
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

2.  Effects of prednisone and deflazacort on vertebral bone mass.

Authors:  C Gennari; B Imbimbo
Journal:  Calcif Tissue Int       Date:  1985-12       Impact factor: 4.333

3.  Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man.

Authors:  T J Hahn; L R Halstead; B Strates; B Imbimbo; D T Baran
Journal:  Calcif Tissue Int       Date:  1980       Impact factor: 4.333

4.  Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment.

Authors:  B Lund; T L Storm; B Lund; F Melsen; L Mosekilde; R B Andersen; C Egmose; O H Sørensen
Journal:  Clin Rheumatol       Date:  1985-06       Impact factor: 2.980

5.  Hypocalcaemia induced by glucocorticoids in a child with hypoparathyroidism treated with 1-alpha-hydroxyvitamin D3.

Authors:  P Vardi; A Benderly; A Etzioni; J Levy; Z Hochberg
Journal:  Eur J Pediatr       Date:  1985-09       Impact factor: 3.183

6.  Effects of prednisone and deflazacort on mineral metabolism and parathyroid hormone activity in humans.

Authors:  C Gennari; B Imbimbo; M Montagnani; M Bernini; P Nardi; L V Avioli
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

7.  Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.

Authors:  T J Hahn; L R Halstead; S L Teitelbaum; B H Hahn
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

8.  Serum 25 (OH) D and 24,25 (OH)2 levels in childhood nephrosis under different therapeutic regimens of steroid administration.

Authors:  K Kano; T Suda
Journal:  Eur J Pediatr       Date:  1982-03       Impact factor: 3.183

9.  25-Hydroxycholecalciferol as an antagonist of adverse corticosteroid effects on phosphate and calcium metabolism in man.

Authors:  R Nuti; A Vattimo; V Turchetti; G Righi
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

10.  Changes in plasma half-life and clearance of 3H-25-hydroxyvitamin D3 in patients with intestinal malabsorption.

Authors:  A J Batchelor; G Watson; J E Compston
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.